Clinical Trials Browser

Phase 2 × Triple Negative Breast Neoplasms × durvalumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT06954480 2025-11-19

DIAMOND

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05215106 2024-07-08

POP-DURVA

Phase 2 Recruiting

Cerebral Palsy, Triple Negative Breast Neoplasms

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02527434 2023-11-15

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2 Completed

64 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03167619 2022-09-13

DORA

Phase 2 Completed

45 enrolled 19 charts

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms